Catalyst Pharmaceuticals (NASDAQ:CPRX) Announces Earnings Results, Beats Estimates By $0.15 EPS

Catalyst Pharmaceuticals (NASDAQ:CPRX) announced its quarterly earnings results on Monday. The biopharmaceutical company reported $0.79 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.15, FiscalAI reports. The company had revenue of $149.39 million for the quarter, compared to the consensus estimate of $149.52 million. Catalyst Pharmaceuticals had a return on equity of 36.47% and a net margin of 36.39%.

Catalyst Pharmaceuticals Stock Performance

Catalyst Pharmaceuticals stock remained flat at $31.15 on Monday. The company’s stock had a trading volume of 3,678,652 shares, compared to its average volume of 1,617,556. Catalyst Pharmaceuticals has a fifty-two week low of $19.05 and a fifty-two week high of $32.56. The stock has a market capitalization of $3.81 billion, a price-to-earnings ratio of 18.43, a P/E/G ratio of 0.95 and a beta of 0.72. The firm has a 50-day moving average of $25.31 and a two-hundred day moving average of $23.93.

Wall Street Analyst Weigh In

CPRX has been the subject of several research analyst reports. Weiss Ratings reiterated a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a report on Friday, March 27th. Oppenheimer downgraded Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday. Robert W. Baird lowered Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday. Stephens set a $32.00 price target on shares of Catalyst Pharmaceuticals in a report on Thursday. Finally, Cantor Fitzgerald raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Friday, March 27th. Three research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $32.17.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. Creative Planning grew its holdings in Catalyst Pharmaceuticals by 23.8% in the third quarter. Creative Planning now owns 20,285 shares of the biopharmaceutical company’s stock worth $400,000 after purchasing an additional 3,900 shares during the period. Brevan Howard Capital Management LP bought a new stake in shares of Catalyst Pharmaceuticals in the 2nd quarter worth approximately $394,000. State of Wyoming boosted its position in shares of Catalyst Pharmaceuticals by 43.6% in the 2nd quarter. State of Wyoming now owns 18,155 shares of the biopharmaceutical company’s stock worth $394,000 after purchasing an additional 5,508 shares in the last quarter. Commonwealth Equity Services LLC grew its stake in shares of Catalyst Pharmaceuticals by 6.1% in the 4th quarter. Commonwealth Equity Services LLC now owns 16,080 shares of the biopharmaceutical company’s stock worth $375,000 after buying an additional 927 shares during the last quarter. Finally, DRW Securities LLC purchased a new stake in shares of Catalyst Pharmaceuticals in the 4th quarter worth approximately $356,000. 79.22% of the stock is owned by hedge funds and other institutional investors.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).